These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 34002252

  • 1. A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05.
    Hagino H, Sugimoto T, Tanaka S, Sasaki K, Sone T, Nakamura T, Soen S, Mori S.
    Osteoporos Int; 2021 Nov; 32(11):2301-2311. PubMed ID: 34002252
    [Abstract] [Full Text] [Related]

  • 2. Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.
    Mori S, Hagino H, Sugimoto T, Tanaka S, Mitomo Y, Takahashi K, Sone T, Nakamura T, Soen S.
    Osteoporos Int; 2023 Jan; 34(1):189-199. PubMed ID: 36239756
    [Abstract] [Full Text] [Related]

  • 3. Design of a randomized trial of teriparatide followed by alendronate: Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
    Tanaka S, Mori S, Hagino H, Sugimoto T.
    J Bone Miner Metab; 2020 May; 38(3):412-417. PubMed ID: 31894491
    [Abstract] [Full Text] [Related]

  • 4. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M.
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
    [Abstract] [Full Text] [Related]

  • 5. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, ACTIVE Study Investigators.
    JAMA; 2016 Aug 16; 316(7):722-33. PubMed ID: 27533157
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan.
    Mori T, Crandall CJ, Fujii T, Ganz DA.
    Arch Osteoporos; 2021 Apr 17; 16(1):72. PubMed ID: 33866457
    [Abstract] [Full Text] [Related]

  • 7. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J.
    Health Technol Assess; 2005 Jun 17; 9(22):1-160. PubMed ID: 15929857
    [Abstract] [Full Text] [Related]

  • 8. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
    Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR.
    Osteoporos Int; 2009 Dec 17; 20(12):2095-104. PubMed ID: 19350340
    [Abstract] [Full Text] [Related]

  • 9. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.
    Harvey NC, Kanis JA, Odén A, Burge RT, Mitlak BH, Johansson H, McCloskey EV.
    Osteoporos Int; 2015 Nov 17; 26(11):2677-84. PubMed ID: 26092063
    [Abstract] [Full Text] [Related]

  • 10. Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
    Hagino H, Tanaka S, Kuroda T, Mori S, Soen S.
    J Bone Miner Metab; 2024 May 17; 42(3):382-388. PubMed ID: 38755328
    [Abstract] [Full Text] [Related]

  • 11. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A.
    N Engl J Med; 2017 Oct 12; 377(15):1417-1427. PubMed ID: 28892457
    [Abstract] [Full Text] [Related]

  • 12. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P.
    Lancet; 2018 Jan 20; 391(10117):230-240. PubMed ID: 29129436
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium.
    Gielen E, Aldvén M, Kanis JA, Borgström F, Senior E, Willems D.
    Osteoporos Int; 2024 Jul 20; 35(7):1173-1183. PubMed ID: 38565690
    [Abstract] [Full Text] [Related]

  • 14. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS, LOFT Investigators.
    Lancet Diabetes Endocrinol; 2019 Dec 20; 7(12):899-911. PubMed ID: 31676222
    [Abstract] [Full Text] [Related]

  • 15. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
    Albert SG, Reddy S.
    Endocr Pract; 2017 Jul 20; 23(7):841-856. PubMed ID: 28448754
    [Abstract] [Full Text] [Related]

  • 16. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
    Leder BZ, Mitlak B, Hu MY, Hattersley G, Bockman RS.
    J Clin Endocrinol Metab; 2020 Mar 01; 105(3):938-43. PubMed ID: 31674644
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
    Nakamura T, Fukunaga M, Nakano T, Kishimoto H, Ito M, Hagino H, Sone T, Taguchi A, Tanaka S, Ohashi M, Ota Y, Shiraki M.
    Osteoporos Int; 2017 Jan 01; 28(1):389-398. PubMed ID: 27631091
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX.
    Harvey NC, Kanis JA, Odén A, Nakamura T, Shiraki M, Sugimoto T, Kuroda T, Johansson H, McCloskey EV.
    Osteoporos Int; 2015 Sep 01; 26(9):2347-53. PubMed ID: 26092062
    [Abstract] [Full Text] [Related]

  • 19. Comparative analysis of anti-osteoporosis medications in preventing vertebral body fractures after balloon kyphoplasty.
    Ueno M, Tajima Y, Ito S, Tsuji M, Toriumi E, Yoshii A, Otake N, Tanaka H.
    Arch Osteoporos; 2024 Mar 21; 19(1):19. PubMed ID: 38512565
    [Abstract] [Full Text] [Related]

  • 20. Reduced risk of back pain following teriparatide treatment: a meta-analysis.
    Nevitt MC, Chen P, Dore RK, Reginster JY, Kiel DP, Zanchetta JR, Glass EV, Krege JH.
    Osteoporos Int; 2006 Feb 21; 17(2):273-80. PubMed ID: 16142502
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.